✦ LIBER ✦

Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy

✍ Scribed by Giuliani, Giovanni; Grossi, Francesco; de Marinis, Filippo; Walzer, Stefan

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Corrigendum to “Cost-effectiveness analy

✍ Giuliani, Giovanni; Grossi, Francesco; de Marinis, Filippo; Walzer, Stefan 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 78 KB

Corrigendum to “Cost-effectiveness analy

📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 232 KB

Corrigendum to “Cost-effectiveness analy

✍ Giuliani, Giovanni; Grossi, Francesco; de Marinis, Filippo; Walzer, Stefan 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 72 KB

Costs of bevacizumab and pemetrexed for

✍ Bischoff, Helge G.; Heigener, David F.; Walzer, Stefan; Nuijten, Mark 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 129 KB

Costs of bevacizumab and pemetrexed for

✍ Bosch-Barrera, Joaquim; Gil-Bazo, Ignacio 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 90 KB

Effectiveness of bevacizumab- and pemetr

✍ Nuijten, Mark; Heigener, David F.; Bischoff, Helge G.; Chouaid, Christos; Vergne 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 145 KB